Clostridium Difficile-Associated Diarrhea News

Analysis of Data from Two Phase 3 Studies Shows DIFICIDŽ Offered Faster ... - MarketWatch (press release)



Analysis of Data from Two Phase 3 Studies Shows DIFICIDŽ Offered Faster ... 
MarketWatch (press release)
DIFICID is the first antibacterial drug indicated for Clostridium difficile-associated diarrhea (CDAD) to be approved in more than 25 years. It is indicated for the treatment of CDAD in adults 18 years of age or older. DIFICID is administered in 200 mg ...
Results will be presented at the 2012 American Society of Clinical Oncology ... PipelineReview.com (press release)

all 9 news articles » 


Optimer Pharmaceuticals Inc. Stock Downgraded (OPTR) - TheStreet.com



Optimer Pharmaceuticals Inc. Stock Downgraded (OPTR) 
TheStreet.com
It offers fidaxomicin tablets, an antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has a market cap of $728.4 million and is part of the health care sector and drugs industry.

 


Clostridium difficile infection: Managing the risks - Journal of the American Academy of Physician Assistants



Clostridium difficile infection: Managing the risks 
Journal of the American Academy of Physician Assistants
1 Additionally, the FDA recently issued a statement warning patients and providers about an increased risk of Clostridium difficile-associated diarrhea (CDAD) with the use of PPIs. C difficile infection is most commonly associated with antibiotic use.

 


University of Minnesota startup to treat challenging bacterial infection - Medical Xpress



University of Minnesota startup to treat challenging bacterial infection 
Medical Xpress
C. difficile affects several million people and is linked to 14000 deaths per year in the United States, according to the Centers for Disease Control and Prevention. Symptoms of C. difficile infection include fever, nausea, and diarrhea, and most often ...

and more » 


Optimer Pharmaceuticals Reports First Quarter 2012 Financial Results - MarketWatch (press release)



Optimer Pharmaceuticals Reports First Quarter 2012 Financial Results 
MarketWatch (press release)
Optimer developed and is commercializing DIFICIDŽ (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has also received marketing authorization for ...

and more » 


Optimer Pharmaceuticals Reports First Quarter 2012 Financial Results - Sacramento Bee



Optimer Pharmaceuticals Reports First Quarter 2012 Financial Results 
Sacramento Bee
Optimer developed and is commercializing DIFICIDŽ (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has also received marketing authorization for ...
Loss at Optimer in 1Q Zacks.com

all 11 news articles » 


Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule ... - MarketWatch (press release)



Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule ... 
MarketWatch (press release)
Optimer developed and commercialized DIFICIDŽ (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has also received marketing authorization for ...

and more » 


/C O R R E C T I O N -- Optimer Pharmaceuticals, Inc./ - MarketWatch (press release)



/C O R R E C T I O N -- Optimer Pharmaceuticals, Inc./ 
MarketWatch (press release)
Optimer developed and commercialized DIFICIDŽ (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has also received marketing authorization for ...

and more » 


Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule ... - PR Newswire (press release)



Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule ... 
PR Newswire (press release)
Optimer developed and commercialized DIFICIDŽ (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has also received marketing authorization for ...

and more » 


Optimer Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 ... - MarketWatch (press release)



Optimer Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 ... 
MarketWatch (press release)
Optimer developed and commercialized DIFICIDŽ (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has also received marketing authorization for ...

and more »